

Ministério da Educação
Universidade Federal do Triângulo Mineiro, Uberaba, MG
Disciplina de Patologia Geral 


Glomerulopatias

Marlene Antônia dos Reis
mareispatologia@gmail.com

Compartimentos

Vascular

Interstitial



Tubular

Glomerular

Glomerulopatias

Agressão inicia - glomerular

- **Secundária** – doença sistêmica

- **Primária**



Manifestações Clínicas - Glomerulopatias

- 1. Alt urinárias assintomáticas**
 - a) hematúria glomerular isolada**
 - b) Proteinúria isolada**
- 2. síndrome nefrótica**
- 3. síndrome nefrítica**
- 4. IRA (insuficiência aguda – rapidamente progressiva)**
- 5. Doença Renal Crônica**





1 A



1 B

The Renal Biopsy
Patrick D. Walker, MD



Arch Pathol Lab Med. 2009;133:181–188



Córtex

Medular

3 A


3 B




Biópsia Renal




ML-10 gl – paraformaldeído
Formaldeído / Bouin / Metacarn






2 μ m



Compartimentos

Vascular

Interstitial



Tubular

Glomerular

Aguda ^{Inflamação} _{Necrose} Crônica

Interstício

Inflamação

Fibrose

Tubular

Necrose

Atrofia

Tubulite

Vascular

Vasculite

espes. intimal

Necrose

Glomerular

Glomerulite


esclerose (↑matriz)

Necrose

Compartimentos



Vascular

Interstitial




Tubular


Glomerular



Repercussões túbulo intersticiais
Fibrose intersticial / atrofia tubular




Espaço urinário




Podócitos

Espaço urinário




Cel endoteliais

Espaço urinário



Cel mesangiais

Espaço urinário




Polo urinário

Matriz mesangial
Tricrômico Masson



Polo urinário

Matriz Mesangial
PAMS – Methenamine Silver



Polo urinário

Membrana Basal
PAMS – Methenamine Silver




Biópsia Renal




ME-2gl – Glutaraldeído
/ Karnovsky + Vermelho rutênio





ML-10 gl – paraformaldeído
Formaldeído / Bouin / Metacarn







- Diagnósticos:
 - Alt célula
 - Memb basal
 - Matriz mesangial
 - Depósitos estruturados
- Entidades sobrepostas
- Afastar entidades







Barreira de Filtração Glomerular





Tryggvason et al., 2006




Componentes da barreira de filtração glomerular







Magnification	Accelerating Voltage	Operator	BR140439_ME2771e
30000 x	80 kV	Mar	—500 nm—







Biópsia Renal





ME-2gl – Glutaraldeído
/ Karnovsky + Vermelho rutênio





ML-10 gl – paraformaldeído
Formaldeído / Bouin / Metacarn



Magnification	Accelerating Voltage	Operator	BR140439_ME2771e
85000 x	80 kV	Mar	—200 nm—








Biópsia Renal





ME-2gl – Glutaraldeído
/ Karnovsky + Vermelho rutênio

ML-10 gl – paraformaldeído
Formaldeído / Bouin / Metacarn

IF-10gl – IC/compl
A fresco / Meio de transporte



Magnification	Accelerating Voltage	Operator	BR140439_ME2771e
85000 x	80 kV	Mar	—200 nm—



Pesquisa de Imunocomplexos

Imunofluorescência Direta




IF: 10 glom

- IgA
- IgG
- IgM
- *Kappa*
- *Lambda*
- Fibrinogênio
- C1q
- C3
- **Controle negativo**




Normal

- IgA
- IgG
- IgM
- *Kappa*
- *Lambda*
- Fibrinogênio
- C1q
- C3



50 μm






Biópsia Renal





ME-2gl – Glutaraldeído
/ Karnovsky + Vermelho rutênio

ML-10 gl – paraformaldeído
Formaldeído / Bouin / Metacarn



IF-10gl – IC/compl
A fresco / Meio de transporte




- IgA
- IgG
- IgM
- Kappa
- Lambda
- Fibrinogênio
- C1q
- C3




Magnification	Accelerating Voltage	Operator	BR140439_ME2771e
85000 x	80 kV	Mar	200 nm



Número glomérulos




Focal $< 50\%$




Difuso $\geq 50\%$


No glomérulo



Segmentar



Global





- 5 anos de idade
- sexo masculino
- **edema** generalizado há 3 meses
- sem HAS ou hematúria

Exames:

- **proteinúria** = 5g/24h;
- Prot. totais = 3,5g%;
- **Albumina sérica** = 2,3g%;
- Colesterol=501mg%;
- Uréia=64mg%;
- Creatinina = 0,8mg%




Manifestações Clínicas - Glomerulopatias

1. **Alt urinárias assintomáticas**
 - a) **hematúria glomerular isolada**
 - b) **Proteinúria isolada**
2. **síndrome nefrótica**
3. **síndrome nefrítica**
4. **IRA (insuficiência aguda – rapidamente progressiva)**
5. **Doença Renal Crônica**

Síndrome Nefrótica


- Proteinúria
 - $\geq 3,5\text{g/dia}$
 - 50mg/kg/dia (criança)
- hipoproteïnemia - albumina ($< 3\text{g/dl}$)
- edema

Síndrome
Nefrótica




Todos negativos

- IgA
- IgG
- IgM
- *Kappa*
- *Lambda*
- Fibrinogênio
- C1q
- C3



50 μm



Luz
capilar

Luz
capilar

Espaço
urinário

Luz
capilar



Mesângio

Luz
capilar

Luz
capilar

Espaço
urinário

Magnification	Accelerating Voltage	Operator	BR160428_ME3041a
3000 x	80 kV	Mar-ML	—5 µm—



Normal

Glomerulopatia de Lesões Mínimas

Clínica:
Síndrome Nefrótica

Magnification	Accelerating Voltage	Operator	BR160428_ME3041a
12000 x	80 kV	Mar-ML	—1 µm—

Identificação
masculino,
cor branca,
37 anos

Edema generalizado há 9 meses



Ex complementares:

Uprot - 15 a 20g/24h


hipoalbuminemia

hipercolesterolemia



Síndrome Nefrótica




esclerose
Segmentar



Exclui Lesões Mínimas




GESF
Glomeruloesclerose
Segmentar e Focal



Podocitopatias

Genéticos


Nefrina,
Podocina,
A-actinina 4
WT1,
miR193a,
etc.





Reativas: mediadores no microambiente:

- Vírus
- Tóxico
- Mecânicas
- Metabólico
- Imune – med
- outros

Entidades com Imunocomplexos / Complementos





Imunocomplexos:

- Circulantes
- Formação “*in situ*”

36 anos de idade, feminino, cor branca

Há mais ou menos um ano:





- edema vespertino peri-orbitário


Exame físico: edema de mmii ++/4


Exames laboratoriais:



- uréia = 30
- creatinina = 0,8 mg/dl
- **Proteinúria de 24h = 8.424mg**
- Prot totais = 3,9
- **Alb = 1,6**; Glob=2,3; A/G = 0,69
- Colesterol - 432mg/dl

Síndrome Nefrótica














IgG / C3 - Subepithelial – finamente granular - Glomerulopatia Membranosa





Glomerulopatia
Membranosa
Estadio II


Glomerulopatia Membranosa


Primária — Ac anti-receptor Fosfolipase A2

Secundária

- Lupus eritematoso sistêmico
- Sífilis
- Hepatite B
- Neoplasias
- Terapêutica:
 - Ouro
 - Penicilamina
 - Mercúrio
 - Captopril

Imunocomplexos:
- Circulantes
- Formação “*in situ*”






Cel endoteliais


Espaço urinário

Cel mesangiais

Imunocomplexos:

- Circulantes
- Formação “*in situ*”







Normal

Células


Hipercelularidade



Proliferação endocapilar global




Infiltração leucocitária global



Normal

Células


Hipercelularidade



Proliferação endocapilar global




Infiltração leucocitária global



Proliferação extra-capilar = crescente

Nefrite Lúpica


1. **Alt urinárias assintomáticas**
 - a) **hematúria glomerular isolada**
 - b) **Proteinúria isolada**
2. **síndrome nefrótica**
3. **síndrome nefrítica**
4. **IRA (insuficiência aguda – rapidamente progressiva)**
5. **Doença Renal Crônica**



Nefrite Lúpica

IgA, **IgG**, IgM, C3, **C1q**, *kappa*, *lambda*


Classe I






Nefrite Lúpica




Classe III – Focal
Classe IV - Difuso





Lupus
“wireloops”
trombos hialinos


Classe I



Nefrite Lúpica



Classe V



Classe II



Classe III – Focal
Classe IV - Difuso

Nefropatia IgA primária

Doença de Berger

- 1. Alt urinárias assintomáticas**
 - a) hematúria glomerular isolada**
 - b) Proteinúria isolada**
- 2. síndrome nefrótica**
- 3. síndrome nefrítica**
- 4. IRA (insuficiência aguda – rapidamente progressiva)**
- 5. Doença Renal Crônica**

Classificação de Oxford:


Trimarchi H et al., Kidney Int 91:1014-1021;2017

Roberts ISD et al. Kidney Int 76:546–556;2009





Eixo mesangial
Nefropatia IgA



Mesângio

Identificação

- 11 anos de idade
- sexo masculino
- cor branca
- profissão: estudante

História

- Faringite purulenta há 15 dias
- há um dia:
 - **hematúria**
 - **oligúria**
 - edema

Exame físico

- edema generalizado
- **PA = 160x100mmHg**

Exames complementares

- **Creatinina = 4,6mg%**
- Proteinúria de 24h = 1.500mg
- Proteínas totais = 6,1g%
- Albumina = 4,1
- **ASO = 800UTodd**
- FAN = negativo

Manifestações Clínicas - Glomerulopatias


1. **Alt urinárias assintomáticas**
 - a) **hematúria glomerular isolada**
 - b) **Proteinúria isolada**
2. **síndrome nefrótica**
3. **síndrome nefrítica**
4. **IRA (insuficiência aguda – rapidamente progressiva)**
5. **Doença Renal Crônica**

Glomerulopatias



Alterações clínicas

Síndrome Nefrítica




diminuição da TFG




- Oligúria – diminuição do volume urinário
- Hipertensão arterial - retenção de líquido
- Azotemia: retenção de elementos nitrogenados
- Hematúria
- proteinúria variável
- edema (discreto)



Alça Capilar granular grosseiro “humps”



C3, IgG
GNDA






GNDA - Patogenia

Doença do soro aguda

- Von Pirquet

soro albumina-bovina



injetou em coelho



Glomerulopatias


Patogenia

Modelos experimentais
Doença do soro aguda




hipercelularidade

- IC - “Humps”








Estreptococo beta-hemolítico do grupo A




Manifestações Clínicas - Glomerulopatias

1. **Alt urinárias assintomáticas**
 - a) **hematúria glomerular isolada**
 - b) **Proteinúria isolada**
2. **síndrome nefrótica**
3. **síndrome nefrítica**
4. **IRA (insuficiência aguda – rapidamente progressiva)**
5. **Doença Renal Crônica**





Linear = membrana basal



IgG

Diagnóstico Clínico

**IRA – GN rapidamente
progressiva**



Diagnóstico Morfológico



**Glomerulonefrite Crescêntica do tipo I
Glomerulonefrite anti-membrana basal
glomerular**

Glomerulonefrite crescêntica

> 50% dos glomérulos

- Tipo I - ac anti MBG
 - Síndrome de Goodpasture
com hemorragia pulmonar
- GN anti MBG
sem hemorragia pulmonar






Síndrome de Goodpasture


3. Nefrite Nefrotóxica

- Landerman (início século)
- 1934 - Masugi - Nefrite de Masugi

macerado de rim de rato (MBG)
injeta em coelho




soro do coelho
(ac anti MBG do rato)




injeta no rato

GN anti membrana basal glomerular






IgG





Hipercelularidade
ac na MBG - padrão linear

GN anti MBG




Glomerulonefrite crescêntica

≥ 50% dos glomérulos




Tipo I – linear - ac anti MBG -10%



Tipo II – 40%
não linear
depósito IC/C

Tipo III - pauci-imune – 50%
90% - ANCA



Glomerulopatias

Mecanismos imunológicos

I. lesão mediada por anticorpo

- neutrófilo (quimiotaxia):
 - proteases, metabólitos do ácido aracídico, radicais livres de O₂
- complemento (fagocitose/quimiotaxia/ataque à membrana)
- monócitos e macrófagos
- plaquetas
- mesângio: IL1, radicais livres de O₂, metab ácido aracídico
- sistema da coagulação

Glomerulopatias correlação clínico-morfológica

Glomerulopatias:

Lesões mínimas

Membranosa

Esclerose segmentar focal - GESF

Glomerulonefrites:

Membranoproliferativa - GNMP

Proliferativa difusa aguda - GNDA

Crescêntica

Síndrome nefrótica



Síndrome nefrítica
IRA

Manifestações Clínicas - Glomerulopatias

1. **Alt urinárias assintomáticas**
 - a) **hematúria glomerular isolada**
 - b) **Proteinúria isolada**
2. **síndrome nefrótica**
3. **síndrome nefrítica**
4. **IRA (insuficiência aguda – rapidamente progressiva)**
5. **Doença Renal Crônica**



Arthur Cecil Alport (1880-1959)

25.01.1880 – África do Sul

17.04.1959 – Londres - Inglaterra

1902 – Guthrie



1912 – Kendall & Hertz

1927 – associação de
surdez com a “nefrite
hemorrágica familiar
hereditária”

Homem: mais grave

Mulher: menos grave

1972 – Spear & Slusser –
defeito colágeno da
membrana basal glomerular




Normal

Síndrome de Alport


Hematúria






Síndrome de Alport

Hematúria




Doença da Membrana Fina




Colágeno IV

Cadeia	cromossomo	gene
$\alpha 1$	13q34	COL4A1
$\alpha 2$	13q34	COL4A2
$\alpha 3$	2q35	COL4A3
$\alpha 4$	2q35	COL4A4
$\alpha 5$	Xq22	COL4A5
$\alpha 6$	Xq22	COL4A6



$\alpha 5 \text{col IV}$

Alport
Ausência $\alpha 5 \text{col IV}$



Manifestações Clínicas - Glomerulopatias

1. Alt urinárias assintomáticas
 - a) hematúria glomerular isolada
 - b) Proteinúria isolada**
2. síndrome nefrótica
3. síndrome nefrítica
4. IRA (insuficiência aguda – rapidamente progressiva)
5. Doença Renal Crônica

Diabetes *Mellitus*


Hiperglicemia

Nefropatia
Retinopatía
Neuropatia
Vaculopatía


Vasculares



Membrana basal
Hialinose arteríola
Aterosclerose



Kumar et al: Robbins & Cotran Pathologic Basis of Disease, 8th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



MBG = 300 a 400nm normal
(mulher-395nm; homem-430nm)

Diabetes:

- 1,5 a 2,5 anos - aumento da espessura
- fases iniciais=1200nm.
- avançado: 3000 a 4000nm

Nefropatia Dibética

Pathologic Classification of Diabetic Nephropathy

Thijs W. Cohen Tervaert,* Antien L. Mooyaart,* Kerstin Amann,† Arthur H. Cohen,‡ H. Terence Cook,§ Cinthia B. Drachenberg,|| Franco Ferrario,¶ Agnes B. Fogo,** Mark Haas,‡ Emile de Heer,* Kensuke Joh,†† Laure H. Noël,‡‡ Jai Radhakrishnan,§§ Surya V. Seshan,|| Ingeborg M. Bajema,* and Jan A. Bruijn,* on behalf of the Renal Pathology Society

J Am Soc Nephrol 21: 556–563, 2010.


Table 1. Glomerular classification of DN

Class	Description	Inclusion Criteria
I	Mild or nonspecific LM changes and EM-proven GBM thickening	Biopsy does not meet any of the criteria mentioned below for class II, III, or IV GBM > 395 nm in female and >430 nm in male individuals 9 years of age and older ^a
IIa	Mild mesangial expansion	Biopsy does not meet criteria for class III or IV Mild mesangial expansion in >25% of the observed mesangium
IIb	Severe mesangial expansion	Biopsy does not meet criteria for class III or IV Severe mesangial expansion in >25% of the observed mesangium
III	Nodular sclerosis (Kimmelstiel–Wilson lesion)	Biopsy does not meet criteria for class IV At least one convincing Kimmelstiel–Wilson lesion
IV	Advanced diabetic glomerulosclerosis	Global glomerular sclerosis in >50% of glomeruli Lesions from classes I through III



Nefropatia Diabética Classe III


BR110660_TM, 20x2,0



BR110660_HE, 20x2,0

Sem IC

Vermelho congo negativo



Pathologic Classification of Diabetic Nephropathy

Thijs W. Cohen Tervaert,* Antien L. Mooyaart,* Kerstin Amann,† Arthur H. Cohen,‡
H. Terence Cook,§ Cinthia B. Drachenberg,|| Franco Ferrario,¶ Agnes B. Fogo,**
Mark Haas,‡ Emile de Heer,* Kensuke Joh,†† Laure H. Noël,‡‡ Jai Radhakrishnan,§§
Surya V. Seshan,|| Ingeborg M. Bajema,* and Jan A. Bruijn,* on behalf of the Renal
Pathology Society

J Am Soc Nephrol 21: 556–563, 2010.

Table 1. Glomerular classification of DN

Class	Description	Inclusion Criteria
I	Mild or nonspecific LM changes and EM-proven GBM thickening	Biopsy does not meet any of the criteria mentioned below for class II, III, or IV GBM > 395 nm in female and >430 nm in male individuals 9 years of age and older ^a
IIa	Mild mesangial expansion	Biopsy does not meet criteria for class III or IV Mild mesangial expansion in >25% of the observed mesangium
IIb	Severe mesangial expansion	Biopsy does not meet criteria for class III or IV Severe mesangial expansion in >25% of the observed mesangium
III	Nodular sclerosis (Kimmelstiel–Wilson lesion)	Biopsy does not meet criteria for class IV At least one convincing Kimmelstiel–Wilson lesion
IV	Advanced diabetic glomerulosclerosis	Global glomerular sclerosis in >50% of glomeruli Lesions from classes I through III







Fioretto & Mauer, 2007

Diabetes *Mellitus*


“capsular drop”

- fortemente sugestivo de diabetes
- hialinose entre MB e epitélio da cápsula de Bowman
- prata negativo





“fibrin cap”

- entre MBG e endotélio
- proteínas e lipídeo



10 μm - Vermelho Congo






Vermelho Congo

Luz comum


Amiloidose



Luz Polarizada



β -fibrillose
Amiloidose
8-12nm





EM – 30.000X

Amiloidose

produção

degradação

- Doenças Inflamatórias (com ou sem infecção)
- Alt Imune
- Hereditárias (mutação)



Amiloidose Renal – Amiloidose sistêmica

> 30

AL **light chain Ig**

AA **Serum Protein A**

A β 2M **β 2 microglobulin**

ALECT2 **Chemotactic Factor Leucocyte 2**

AFib **A alfa-chain fibrinogen**

ATTR **transtiretin**

AApoAI **Apolipoprotein AI**

AApoAII **Apolipoprotein AII**

ALys **lysozyme**




AGel **Gelsolin**

ACys **Cystatin C**

Proteínas amiloidogênicas
São conhecidas

BR100550

Glu526Val
Mutação
um alelo



Amyloid

The Journal of Protein Folding Disorders

<http://informahealthcare.com/amy>
ISSN: 1350-6129 (print), 1744-2818 (electronic)

Amyloid, Early Online: 1–4

© 2013 Informa UK Ltd. DOI: 10.3109/13506129.2012.763029

informa
healthcare

CASE REPORT

Fibrinogen A alpha-chain amyloidosis: report of the first case in Latin America


Juliana Reis Machado¹, Marcos Vinícius da Silva², Precil Diego Miranda de Menezes Neves¹, Flavia Aparecida de Oliveira³, Rosana Rosa Miranda Corrêa¹, Willians Vinícius Dutra Rodrigues⁴, Merrill Benson⁵, and Marlene Antônia dos Reis¹




Pesquisa de Imunocomplexos - IC

Fluorescência
natural


Controle negativo



Lipídeos



Sudan




20 μm

Doenças de Depósitos em Lisossomos

(deficiência enzimática)


- Doença de Gaucher - glicosilceramidase
- Doença de Fabry – alfa-galactosidase
- Doença de Niemann-Pick - esfingomielinase
- Doença de Tay-Sachs - hexosaminase A



Accelerating Voltage 80000 kV
Magnification 3000 x

Br090472_1819


5 μ m



Doença Renal Crônica


Glomerulopatia crônica

≥90% glomérulos com esclerose global
Fibrose intersticial e atrofia tubular





Transplante renal ao longo do tempo

Transplante



Perda Enxerto



Rim Nativo



Lesões provenientes do doador





Rim Transplantado

Transplante renal ao longo do tempo

Transplante

Perda Enxerto



Isquemia
NTA

Doença
/Lesões
doador

Transplante renal ao longo do tempo

Transplante

Perda Enxerto

Rejeição Aguda (celular/humoral)

Rejeição subclínica (celular/humoral)

Rejeição crônica (celular/humoral)

Isquemia
NTA

Doença
/Lesões
doador

Transplante renal ao longo do tempo

Transplante

Perda Enxerto

Rejeição Aguda (celular/humoral)

Rejeição subclínica (celular/humoral)


Rejeição crônica (celular/humoral)

Isquemia
NTA

Nefrotoxicidade

Doença
/Lesões
doador

Doença recorrente



doença do rim nativo
aparece no transplante

GESF
DDD



Rim Nativo

Rim Transplantado

Rim Nativo



Doença *de novo*

doença no transplante diferente da doença no rim nativo

Rim Transplantado



Transplante renal ao longo do tempo

Transplante

Perda Enxerto

Rejeição Aguda (celular/humoral)

Rejeição subclínica (celular/humoral)

Rejeição crônica (celular/humoral)

Isquemia
NTA

Nefrotoxicidade

Doença
/Lesões
doador

Doença recorrente

Doença *de novo*

Transplante renal ao longo do tempo

Transplante

Perda Enxerto

Rejeição Aguda (celular/humoral)

Rejeição subclínica (celular/humoral)

Rejeição crônica (celular/humoral)

Isquemia
NTA

Nefrotoxicidade

Imunossupressão:

Infecções: NTI - Nefrite Polioma vírus

Neoplasias: Doença linfoproliferativa

Epiteliais

Doença recorrente

Doença *de novo*

Doença
/Lesões
doador




Biópsia Renal





ME-2gl – Glutaraldeído
/ Karnovsky + Vermelho rutênio

ML-10 gl – paraformaldeído
Formaldeído / Bouin / Metacarn



IF-10gl – IC/compl
A fresco / Meio de transporte



- IgA
- IgG
- IgM
- Kappa
- Lambda
- Fibrinogênio
- C1q
- C3







Magnification	Accelerating Voltage	Operator	BR140439_ME2771e
85000 x	80 kV	Mar	200 nm





Informações Clínicas





Ministério da Educação
Universidade Federal do Triângulo Mineiro, Uberaba, MG
Disciplina de Patologia Geral 

Glomerulopatias

Marlene Antônia dos Reis
mareispatologia@gmail.com